Skip to main content
SpringerLink
Log in

Lymphoma

  • Chapter
  • First Online:
Decision Tools for Radiation Oncology

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 1397 Accesses

Abstract

Hodgkin and non-Hodgkin lymphoma represent a diverse spectrum of distinct diseases that arise from the lymphoid system. Lymphomas are characterized by significant biological diversity, heterogeneous presentations, distinct treatment approaches, and ever-changing classification schemes. Prognostic scoring systems have been developed for the most common subtypes using standard clinical and pathological factors. These scoring systems are commonly utilized in clinical practice to guide treatment and assess prognosis. More refined methods of understanding the underlying biology, such as gene expression profiling, are currently being explored. Response to treatment by radiological imaging, particularly positron emission tomography, is instrumental in clinical practice and also has significant prognostic significance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

HL:

Hodgkin lymphoma

NHL:

Non-Hodgkin lymphoma

NLPHL:

Nodular lymphocyte predominant Hodgkin lymphoma

GHSG:

German Hodgkin Study Group

ABVD:

Doxorubicine, bleomycin, vinblastine, dacarbazine

BEACOPP:

Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone

DLBCL:

Diffuse large B-cell lymphoma

IPI:

International prognostic index

FL:

Follicular lymphoma

FLIPI:

Follicular lymphoma international prognostic index

PET:

Positron emission tomography

ALCL:

Anaplastic large cell lymphoma

MALT:

Mucosa associated lymphoid tissue

PCNSL:

Primary central nervous system lymphoma

MF:

Mycosis fungoides

WBRT:

Whole brain radiation therapy

LDH:

Lactate dehydrogenase

References

  • Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18(17):3144–3150

    CAS  PubMed  Google Scholar 

  • Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta M, DeAngelis LM (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24(36):5711–5715. doi:10.1200/JCO.2006.08.2941 JCO.2006.08.2941 [pii]

    PubMed  Google Scholar 

  • Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ (2010) Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28(31):4730–4739. doi:10.1200/JCO.2009.27.7665 JCO.2009.27.7665 [pii]

    PubMed  Google Scholar 

  • Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van ‘t Veer MB, Lybeert ML, Keuning JJ, Carde P, Girinsky T, van der Maazen RW, Tomsic R, Vovk M, van Hoof A, Demeestere G, Lugtenburg PJ, Thomas J, Schroyens W, De Boeck K, Baars JW, Kluin-Nelemans JC, Carrie C, Aoudjhane M, Bron D, Eghbali H, Smit WG, Meerwaldt JH, Hagenbeek A, Pinna A, Henry-Amar M (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24):2396–2406

    PubMed  Google Scholar 

  • Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van ‘t Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5):1878–1886. doi:10.1182/blood-2006-07-034405 blood-2006-07-034405 [pii]

    CAS  PubMed  Google Scholar 

  • Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511. doi:10.1038/35000501

    CAS  PubMed  Google Scholar 

  • Aviles A, Delgado S (1998) A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin’s disease with bulky disease. Clin Lab Haematol 20(2):95–99

    CAS  PubMed  Google Scholar 

  • Aviles A, Delgado S, Nambo MJ, Alatriste S, Diaz-Maqueo JC (1994) Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30(4):799–803

    CAS  PubMed  Google Scholar 

  • Aviles A, Fernandezb R, Perez F, Nambo MJ, Neri N, Talavera A, Castaneda C, Gonzalez M, Cleto S (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45(7):1385–1389

    PubMed  Google Scholar 

  • Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS (2011) End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol 22(4):910–915. doi:10.1093/annonc/mdq549 mdq549 [pii]

    CAS  PubMed  Google Scholar 

  • Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, Roman E, Jack A (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28(20):3360–3365. doi:10.1200/JCO.2009.26.3947 JCO.2009.26.3947 [pii]

    CAS  PubMed  Google Scholar 

  • Bernard M, Tsang RW, Le LW, Hodgson DC, Sun A, Wells W, Kukreti V, Kuruvilla J, Crump M, Gospodarowicz MK (2013) Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma 54(2):261–267. doi:10.3109/10428194.2012.711828

    CAS  PubMed  Google Scholar 

  • Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J (2004) Primary non-Hodgkin’s lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59(2):501–508. doi:10.1016/j.ijrobp.2003.11.001 S0360301603022855 [pii]

    PubMed  Google Scholar 

  • Bhatia S, Ramsay NK, Bantle JP, Mertens A, Robison LL (1996) Thyroid Abnormalities after therapy for Hodgkin’s disease in childhood. Oncologist 1(1 & 2):62–67

    PubMed  Google Scholar 

  • Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CT, Fuller LM, Mauch P et al (1995) Incidence of second cancers in patients treated for Hodgkin’s disease. J Natl Cancer Inst 87(10):732–741

    CAS  PubMed  Google Scholar 

  • Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14):2835–2841

    PubMed  Google Scholar 

  • Bonnet C, Fillet G, Mounier N, Ganem G, Molina TJ, Thieblemont C, Ferme C, Quesnel B, Martin C, Gisselbrecht C, Tilly H, Reyes F (2007) CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 25(7):787–792. doi:10.1200/JCO.2006.07.0722 JCO.2006.07.0722 [pii]

    CAS  PubMed  Google Scholar 

  • Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dorken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A (2011) Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29(32):4234–4242. doi:10.1200/JCO.2010.33.9549 JCO.2010.33.9549 [pii]

    CAS  PubMed  Google Scholar 

  • Brennan P, Scelo G, Hemminki K, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Seow A, Pompe-Kirn V, Martos C, Jonasson JG, Colin D, Boffetta P (2005) Second primary cancers among 109 000 cases of non-Hodgkin’s lymphoma. Br J Cancer 93(1):159–166. doi:10.1038/sj.bjc.6602654 6602654 [pii]

    CAS  PubMed Central  PubMed  Google Scholar 

  • Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Maloney DG, Gopal AK (2011) Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29(22):3023–3029. doi:10.1200/JCO.2010.33.7055 JCO.2010.33.7055 [pii]

    PubMed Central  PubMed  Google Scholar 

  • Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26(32):5170–5174. doi:10.1200/JCO.2007.15.1001 JCO.2007.15.1001 [pii]

    PubMed  Google Scholar 

  • Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, Connors JM, Savage KJ (2010) Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 116(16):3797–3806. doi:10.1002/cncr.25117

    PubMed  Google Scholar 

  • Campbell BA, Connors JM, Gascoyne RD, Morris WJ, Pickles T, Sehn LH (2012) Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer 118(17):4156–4165. doi:10.1002/cncr.26687

    PubMed  Google Scholar 

  • Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL (2011) 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 52(3):386–392. doi:10.2967/jnumed.110.082586 jnumed.110.082586 [pii]

    PubMed  Google Scholar 

  • Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, Jain P, Bishop L, Horwich A, Catovsky D (2003) Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 89(1):36–42. doi:10.1038/sj.bjc.6601006 6601006 [pii]

    CAS  PubMed Central  PubMed  Google Scholar 

  • Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM (2010) Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28(1):136–141. doi:10.1200/JCO.2009.24.0945 JCO.2009.24.0945 [pii]

    PubMed  Google Scholar 

  • Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494–5502. doi:10.1158/1078-0432.CCR-09-0113 1078-0432.CCR-09-0113 [pii]

    CAS  PubMed  Google Scholar 

  • Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS (1984) Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 53(4):878–883

    CAS  PubMed  Google Scholar 

  • Corry J, Smith JG, Wirth A, Quong G, Liew KH (1998) Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41(3):615–620 S0360-3016(97)00571-3 [pii]

    CAS  PubMed  Google Scholar 

  • De Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27(26):4239–4246. doi:10.1200/JCO.2008.19.9174 JCO.2008.19.9174 [pii]

    PubMed  Google Scholar 

  • Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R (1998) Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 92(4):1150–1159

    CAS  PubMed  Google Scholar 

  • Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R (1999) Prognostic factor analysis in mycosis fungoides/Sezary syndrome. J Am Acad Dermatol 40(6 Pt 1):914–924 S0190-9622(99)70079-4 [pii]

    CAS  PubMed  Google Scholar 

  • Diehl V, Sextro M, Franklin J, Hansmann ML, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol 17(3):776–783

    CAS  PubMed  Google Scholar 

  • Dorth JA, Chino JP, Prosnitz LR, Diehl LF, Beaven AW, Coleman RE, Kelsey CR (2011) The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol 22(2):405–410. doi:10.1093/annonc/mdq389 mdq389 [pii]

    CAS  PubMed  Google Scholar 

  • Dorth JA, Prosnitz LR, Broadwater G, Diehl LF, Beaven AW, Coleman RE, Kelsey CR (2012) Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging. Int J Radiat Oncol Biol Phys 84(3):762–767. doi:10.1016/j.ijrobp.2011.12.067 S0360-3016(11)03771-0 [pii]

    PubMed  Google Scholar 

  • Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M (2012) Impact of [18F]Fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS. J Clin Oncol 30(35):4317–4322. doi:10.1200/JCO.2012.43.0934 JCO.2012.43.0934 [pii]

    CAS  PubMed  Google Scholar 

  • Eich HT, Muller RP, Engenhart-Cabillic R, Lukas P, Schmidberger H, Staar S, Willich N (2008) Involved-node radiotherapy in early-stage Hodgkin’s lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 184(8):406–410

    PubMed  Google Scholar 

  • Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, Ho A, Dorken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Dohner H, Borchmann P, Muller-Hermelink HK, Muller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27):4199–4206. doi:10.1200/JCO.2010.29.8018 JCO.2010.29.8018 [pii]

    PubMed  Google Scholar 

  • Engert A (2012) Radiotherapy in early-stage Hodgkin lymphoma. The ASCO Post, 15 June 2012

    Google Scholar 

  • Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19):3601–3608

    PubMed  Google Scholar 

  • Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, Koch P, Hanel M, Pfreundschuh M, Wilhelm M, Trumper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Muller-Hermelink HK, Hasenclever D, Loffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27(27):4548–4554. doi:10.1200/JCO.2008.19.8820 JCO.2008.19.8820 [pii]

    PubMed  Google Scholar 

  • Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7):640–652. doi:10.1056/NEJMoa1000067

    CAS  PubMed  Google Scholar 

  • Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Kral Z, Fuchs M, Hallek M, Kanz L, Dohner H, Dorken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Muller RP, Dietlein M, Borchmann P, Diehl V (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 379(9828):1791–1799. doi:10.1016/S0140-6736(11)61940-5 S0140-6736(11)61940-5 [pii]

    CAS  PubMed  Google Scholar 

  • Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA Jr, Fisher RI (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 120(11):903–912

    CAS  PubMed  Google Scholar 

  • Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A (1999) ALK + lymphoma: clinico-pathological findings and outcome. Blood 93(8):2697–2706

    CAS  PubMed  Google Scholar 

  • Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555–4562. doi:10.1200/JCO.2008.21.3991 JCO.2008.21.3991 [pii]

    PubMed  Google Scholar 

  • Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van’t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19):1916–1927. doi:10.1056/NEJMoa064601 357/19/1916 [pii]

    CAS  PubMed  Google Scholar 

  • Ferreri AJ, Dell’Oro S, Reni M, Ceresoli GL, Cozzarini C, Ponzoni M, Villa E (2000) Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B-cell lymphomas. Oncology 58(3):219–226 ocl58219 [pii]

    CAS  PubMed  Google Scholar 

  • Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21(2):266–272

    PubMed  Google Scholar 

  • Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126. doi:10.1200/JCO.2005.09.131 JCO.2005.09.131 [pii]

    CAS  PubMed  Google Scholar 

  • Franklin JG, Paus MD, Pluetschow A, Specht L (2005) Chemotherapy, radiotherapy and combined modality for Hodgkin’s disease, with emphasis on second cancer risk. Cochrane Database Syst Rev (4):CD003187. doi:10.1002/14651858.CD003187.pub2

  • Friedberg JW (2012) Double-hit diffuse large B-cell lymphoma. J Clin Oncol 30(28):3439–3443. doi:10.1200/JCO.2012.43.5800 JCO.2012.43.5800 [pii]

    CAS  PubMed  Google Scholar 

  • Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK (2009) Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 27(8):1202–1208. doi:10.1200/JCO.2008.18.1495 JCO.2008.18.1495 [pii]

    PubMed Central  PubMed  Google Scholar 

  • Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, Cerhan JR, Zelenetz AD, Hirata J, Miller TP (2012) Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30(27):3368–3375. doi:10.1200/JCO.2011.40.6546 JCO.2011.40.6546 [pii]

    CAS  PubMed Central  PubMed  Google Scholar 

  • Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24):3746–3752. doi:10.1200/JCO.2007.11.6525 JCO.2007.11.6525 [pii]

    CAS  PubMed  Google Scholar 

  • Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM, Armitage JO (2006) Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol 17(6):920–927. doi:10.1093/annonc/mdl039 mdl039 [pii]

    CAS  PubMed  Google Scholar 

  • Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93(11):3913–3921

    CAS  PubMed  Google Scholar 

  • Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E (2010) The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 115(8):1530–1533. doi:10.1182/blood-2009-08-236570 blood-2009-08-236570 [pii]

    CAS  PubMed  Google Scholar 

  • Gervais-Fagnou DD, Girouard C, Laperriere N, Pintillie M, Goss PE (1999) Breast cancer in women following supradiaphragmatic irradiation for Hodgkin’s disease. Oncology 57(3):224–231 12035 [pii] 12035

    CAS  PubMed  Google Scholar 

  • Girardi M, Heald PW, Wilson LD (2004) The pathogenesis of mycosis fungoides. N Engl J Med 350(19):1978–1988. doi:10.1056/NEJMra032810 350/19/1978 [pii]

    CAS  PubMed  Google Scholar 

  • Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88(2):202–210. doi:10.1016/j.radonc.2008.05.012 S0167-8140(08)00241-7 [pii]

    PubMed  Google Scholar 

  • Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P (1998) Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol 46(1):51–62 S0167814097001254 [pii]

    CAS  PubMed  Google Scholar 

  • Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Tsang RW (2010) Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 116(16):3815–3824. doi:10.1002/cncr.25226

    PubMed  Google Scholar 

  • Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, Stevenson MA, Mauch P (2006) Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 64(3):928–934. doi:10.1016/j.ijrobp.2005.08.010 S0360-3016(05)02375-8 [pii]

    PubMed  Google Scholar 

  • Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24(19):3121–3127. doi:10.1200/JCO.2005.05.1003 JCO.2005.05.1003 [pii]

    CAS  PubMed  Google Scholar 

  • Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106(4):1376–1381. doi:10.1182/blood-2005-01-0272 2005-01-0272 [pii]

    CAS  PubMed  Google Scholar 

  • Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK (2012) Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys 83(5):e647–e654. doi:10.1016/j.ijrobp.2012.01.060 S0360-3016(12)00133-2 [pii]

    PubMed  Google Scholar 

  • Hancock SL, Cox RS, McDougall IR (1991) Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 325(9):599–605. doi:10.1056/NEJM199108293250902

    CAS  PubMed  Google Scholar 

  • Hancock SL, Tucker MA, Hoppe RT (1993a) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85(1):25–31

    CAS  PubMed  Google Scholar 

  • Hancock SL, Tucker MA, Hoppe RT (1993b) Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 270(16):1949–1955

    CAS  PubMed  Google Scholar 

  • Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. doi:10.1182/blood-2003-05-1545 2003-05-1545 [pii]

    CAS  PubMed  Google Scholar 

  • Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dolken G, Naumann R, Knauf W, Freund M, Rohrberg R, Hoffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grunhagen U (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25(15):1986–1992. doi:10.1200/JCO.2006.06.4618 JCO.2006.06.4618 [pii]

    CAS  PubMed  Google Scholar 

  • Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725–3732

    CAS  PubMed  Google Scholar 

  • Horning SJ, Weller E, Kim K, Earle JD, O’Connell MJ, Habermann TM, Glick JH (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22(15):3032–3038. doi:10.1200/JCO.2004.06.088 JCO.2004.06.088 [pii]

    CAS  PubMed  Google Scholar 

  • Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558–565. doi:10.1182/blood-2007-06-095331 blood-2007-06-095331 [pii]

    CAS  PubMed  Google Scholar 

  • Hull MC, Morris CG, Pepine CJ, Mendenhall NP (2003) Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 290(21):2831–2837

    CAS  PubMed  Google Scholar 

  • Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1):52–59

    CAS  PubMed  Google Scholar 

  • Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD (2005) Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23(21):4652–4661. doi:10.1200/JCO.2005.01.891 JCO.2005.01.891 [pii]

    PubMed  Google Scholar 

  • Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578. doi:10.1200/JCO.2006.08.2305 JCO.2006.08.2305 [pii]

    PubMed  Google Scholar 

  • Kim YH, Bishop K, Varghese A, Hoppe RT (1995) Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol 131(9):1003–1008

    CAS  PubMed  Google Scholar 

  • Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139(7):857–866. doi:10.1001/archderm.139.7.857 139/7/857 [pii]

    PubMed  Google Scholar 

  • Klapper W, Stoecklein H, Zeynalova S, Ott G, Kosari F, Rosenwald A, Loeffler M, Trumper L, Pfreundschuh M, Siebert R (2008) Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Leukemia 22(12):2226–2229. doi:10.1038/leu.2008.230 leu2008230 [pii]

    CAS  PubMed  Google Scholar 

  • Koontz BF, Kirkpatrick JP, Clough RW, Prosnitz RG, Gockerman JP, Moore JO, Prosnitz LR (2006) Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin’s disease: cure balanced against complications. J Clin Oncol 24(4):605–611

    PubMed  Google Scholar 

  • Kupeli S, Hazirolan T, Varan A, Akata D, Alehan D, Hayran M, Besim A, Buyukpamukcu M (2010) Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin’s lymphoma. J Clin Oncol 28(6):1025–1030. doi:10.1200/JCO.2009.25.2627 JCO.2009.25.2627 [pii]

    PubMed  Google Scholar 

  • Laskar S, Gupta T, Vimal S, Muckaden MA, Saikia TK, Pai SK, Naresh KN, Dinshaw KA (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22(1):62–68

    CAS  PubMed  Google Scholar 

  • Lavey RS, Eby NL, Prosnitz LR (1990) Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 66(1):80–88

    CAS  PubMed  Google Scholar 

  • Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM (2003) Limited-stage mantle-cell lymphoma. Ann Oncol 14(10):1555–1561

    CAS  PubMed  Google Scholar 

  • Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323. doi:10.1056/NEJMoa0802885 359/22/2313 [pii]

    CAS  PubMed  Google Scholar 

  • Levy M, Copie-Bergman C, Gameiro C, Chaumette MT, Delfau-Larue MH, Haioun C, Charachon A, Hemery F, Gaulard P, Leroy K, Delchier JC (2005) Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 23(22):5061–5066

    PubMed  Google Scholar 

  • Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH (2003) CD30 + cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 49(6):1049–1058. doi:10.1016/S0190 S0190962203024848 [pii]

    PubMed  Google Scholar 

  • Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P (2011) Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 100(1):86–92. doi:10.1016/j.radonc.2011.05.013 S0167-8140(11)00205-2 [pii]

    PubMed  Google Scholar 

  • Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14(4):1282–1290

    CAS  PubMed  Google Scholar 

  • Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26(28):4579–4586. doi:10.1200/JCO.2007.13.5376 JCO.2007.13.5376 [pii]

    CAS  PubMed  Google Scholar 

  • Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, Pruneri G, Preda L, Piperno G, Gospodarowicz M, Cavalli F, Moreno Gomez H (2009) Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy (IELSG 4) [corrected]. Leuk Lymphoma 50(6):925–931. doi:10.1080/10428190902912478 911751509 [pii]

    CAS  PubMed  Google Scholar 

  • Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, Ott G, Rosenwald A, Braziel RM, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200–207. doi:10.1200/JCO.2010.30.0368 JCO.2010.30.0368 [pii]

    PubMed Central  PubMed  Google Scholar 

  • Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366(5):399–408. doi:10.1056/NEJMoa1111961

    CAS  PubMed Central  PubMed  Google Scholar 

  • Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, Maisey MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin’s Lymphoma-comparison with CT. Leuk Lymphoma 39(5–6):543–553 I308J001131 [pii]

    CAS  PubMed  Google Scholar 

  • Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339(1):21–26

    CAS  PubMed  Google Scholar 

  • Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC (2006) Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 107(7):2912–2919. doi:10.1182/blood-2005-08-3392 2005-08-3392 [pii]

    CAS  PubMed  Google Scholar 

  • Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, Hoskin PJ, Linch DC (2006) Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J Clin Oncol 24(10):1568–1574. doi:10.1200/JCO.2005.04.2200 JCO.2005.04.2200 [pii]

    PubMed  Google Scholar 

  • Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ, Oudejans JJ (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B-cell lymphoma. J Pathol 208(5):714–723. doi:10.1002/path.1924

    CAS  PubMed  Google Scholar 

  • Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, Sun A, Hodgson DC (2008) Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 49(8):1486–1493. doi:10.1080/10428190802140873 793642260 [pii]

    CAS  PubMed  Google Scholar 

  • Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, Kadin ME, Pattengale P, Davis PC, Hutchinson RJ, White K (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 20(18):3765–3771

    PubMed  Google Scholar 

  • Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M (2001) Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 48(4):454–460

    CAS  PubMed Central  PubMed  Google Scholar 

  • Natkunam Y, Farinha P, Hsi ED, Hans CP, Tibshirani R, Sehn LH, Connors JM, Gratzinger D, Rosado M, Zhao S, Pohlman B, Wongchaowart N, Bast M, Avigdor A, Schiby G, Nagler A, Byrne GE, Levy R, Gascoyne RD, Lossos IS (2008) LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 26(3):447–454. doi:10.1200/JCO.2007.13.0690 JCO.2007.13.0690 [pii]

    CAS  PubMed  Google Scholar 

  • Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20(8):2101–2108

    PubMed  Google Scholar 

  • Niitsu N, Okamoto M, Miura I, Hirano M (2009) Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia 23(4):777–783. doi:10.1038/leu.2008.344 leu2008344 [pii]

    CAS  PubMed  Google Scholar 

  • Nogova L, Reineke T, Eich HT, Josting A, Muller-Hermelink HK, Wingbermuhle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Muller RP, Diehl V, Engert A (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16(10):1683–1687. doi:10.1093/annonc/mdi323 mdi323 [pii]

    CAS  PubMed  Google Scholar 

  • Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, Bredenfeld H, Skripnitchenko R, Muller RP, Muller-Hermelink HK, Diehl V, Engert A (2008) Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26(3):434–439. doi:10.1200/JCO.2007.11.8869 JCO.2007.11.8869 [pii]

    PubMed  Google Scholar 

  • Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR (2012) Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. doi:10.1093/annonc/mds429 mds429 [pii]

    PubMed  Google Scholar 

  • Noordijk EM, Thomas J, Ferme C, van ‘t Veer MB, Brice P, Divine M, Morschhauser F, Carde P, Eghbali H, Henry-Amar M (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). Proc ASCO 23(June 1 Supplement):6505

    Google Scholar 

  • Noy A, Yahalom J, Zaretsky L, Brett I, Zelenetz AD (2005) Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapy. J Clin Oncol 23(16):3768–3772. doi:10.1200/JCO.2005.10.018 23/16/3768 [pii]

    PubMed  Google Scholar 

  • Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppa S (2009) Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol 22(8):1094–1101. doi:10.1038/modpathol.2009.73 modpathol200973 [pii]

    CAS  PubMed  Google Scholar 

  • Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62(10):1595–1600. doi:10.1001/archneur.62.10.1595 62/10/1595 [pii]

    PubMed  Google Scholar 

  • Ono S, Kato M, Takagi K, Kodaira J, Kubota K, Matsuno Y, Komatsu Y, Asaka M (2010) Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol 25(4):804–809. doi:10.1111/j.1440-1746.2009.06204.x JGH6204 [pii]

    PubMed  Google Scholar 

  • Pavlovsky S, Maschio M, Santarelli MT, Muriel FS, Corrado C, Garcia I, Schwartz L, Montero C, Sanahuja FL, Magnasco O et al (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 80(18):1466–1473

    CAS  PubMed  Google Scholar 

  • Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21(24):4489–4495. doi:10.1200/JCO.2003.04.056 JCO.2003.04.056 [pii]

    CAS  PubMed  Google Scholar 

  • Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391

    CAS  PubMed  Google Scholar 

  • Phan J, Mazloom A, Jeffrey Medeiros L, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS (2010) Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170–4176. doi:10.1200/JCO.2009.27.3441 JCO.2009.27.3441 [pii]

    PubMed  Google Scholar 

  • Picardi M, De Renzo A, Pane F, Nicolai E, Pacelli R, Salvatore M, Rotoli B (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 48(9):1721–1727. doi:10.1080/10428190701559140 781796832 [pii]

    PubMed  Google Scholar 

  • Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, Giunta F, Ladetto M, Limerutti G, Menga M, Nicolosi M, Priolo G, Puccini B, Rigacci L, Salvi F, Vaggelli L, Passera R, Bisi G, Vitolo U (2012) Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119(9):2066–2073. doi:10.1182/blood-2011-06-359943 blood-2011-06-359943 [pii]

    CAS  PubMed  Google Scholar 

  • Pugh TJ, Ballonoff A, Newman F, Rabinovitch R (2010) Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer 116(16):3843–3851. doi:10.1002/cncr.25149

    PubMed  Google Scholar 

  • Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD (2010) Prognostic factors in follicular lymphoma. J Clin Oncol 28(17):2902–2913. doi:10.1200/JCO.2009.26.1693 JCO.2009.26.1693 [pii]

    CAS  PubMed  Google Scholar 

  • Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947

    PubMed  Google Scholar 

  • Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, Megraud F, Palazzo L, de Mascarel A, Molina T, Rambaud JL (2001) Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48(3):297–303

    CAS  PubMed  Google Scholar 

  • Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, Schulz H, Kraemer W, Boersch G, Rohde P, Seifert E, Stolte M, Bayerdoerffer E (1997) Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 113(4):1087–1090 S0016508597004599 [pii]

    CAS  PubMed  Google Scholar 

  • Safar V, Dupuis J, Itti E, Jardin F, Fruchart C, Bardet S, Vera P, Copie-Bergman C, Rahmouni A, Tilly H, Meignan M, Haioun C (2012) Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30(2):184–190. doi:10.1200/JCO.2011.38.2648 JCO.2011.38.2648 [pii]

    CAS  PubMed  Google Scholar 

  • Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Ferme C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377(9759):42–51. doi:10.1016/S0140-6736(10)62175-7 S0140-6736(10)62175-7 [pii]

    CAS  PubMed  Google Scholar 

  • Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, Farber LR, Kiehl RK, Cardinale J, Cooper DL (1996) Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14(9):2435–2443

    CAS  PubMed  Google Scholar 

  • Sasse S, Klimm B, Gorgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Muller RP, Diehl V, Eich HT, Borchmann P, Engert A (2012) Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin’s lymphoma. Ann Oncol. doi:10.1093/annonc/mds110 mds110 [pii]

    PubMed  Google Scholar 

  • Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496–5504. doi:10.1182/blood-2008-01-134270 blood-2008-01-134270 [pii]

    CAS  PubMed  Google Scholar 

  • Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, Horsman DE, Gascoyne RD (2009) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114(17):3533–3537. doi:10.1182/blood-2009-05-220095 blood-2009-05-220095 [pii]

    CAS  PubMed  Google Scholar 

  • Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM (2011) Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. Blood 118(17):4585–4590. doi:10.1182/blood-2011-07-365932 blood-2011-07-365932 [pii]

    CAS  PubMed  Google Scholar 

  • Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bolling T, Dieckmann K, Potter R, Heinecke A, Bramswig J, Dorffel W (2010) Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 55(6):1145–1152. doi:10.1002/pbc.22664

    PubMed  Google Scholar 

  • Schlembach PJ, Wilder RB, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD (2000) Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 48(4):1107–1110 S0360-3016(00)00760-4 [pii]

    CAS  PubMed  Google Scholar 

  • Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, Canninga-van Dijk MR, Geerts ML, Hebeda KM, Kluin PM, Lam KH, Meijer CJ, Willemze R (2007a) Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol 25(12):1581–1587. doi:10.1200/JCO.2006.09.6396 JCO.2006.09.6396 [pii]

    PubMed  Google Scholar 

  • Senff NJ, Hoefnagel JJ, Neelis KJ, Vermeer MH, Noordijk EM, Willemze R (2007b) Results of radiotherapy in 153 primary cutaneous B-Cell lymphomas classified according to the WHO-EORTC classification. Arch Dermatol 143(12):1520–1526. doi:10.1001/archderm.143.12.1520 143/12/1520 [pii]

    PubMed  Google Scholar 

  • Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112(5):1600–1609. doi:10.1182/blood-2008-04-152850 blood-2008-04-152850 [pii]

    CAS  PubMed  Google Scholar 

  • Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25(30):4730–4735. doi:10.1200/JCO.2007.12.5062 25/30/4730 [pii]

    CAS  PubMed  Google Scholar 

  • Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T, Kato E, Ishihara S, Sougawa M, Kenjo M, Kawamura T, Hayabuchi N (2005) Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys 62(3):809–813. doi:10.1016/j.ijrobp.2004.12.043 S0360-3016(04)03166-9 [pii]

    PubMed  Google Scholar 

  • Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH (2011) Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol 22(5):1164–1169 10.1093/annonc/mdq574mdq574 [pii]

    CAS  PubMed  Google Scholar 

  • Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte Trials. J Clin Oncol 30(32):3939–3946. doi:10.1200/JCO.2012.42.2345 JCO.2012.42.2345 [pii]

    PubMed  Google Scholar 

  • Smith BD, Glusac EJ, McNiff JM, Smith GL, Heald PW, Cooper DL, Wilson LD (2004) Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol 22(4):634–639. doi:10.1200/JCO.2004.08.044 JCO.2004.08.044 [pii]

    PubMed  Google Scholar 

  • Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258–1265

    CAS  PubMed  Google Scholar 

  • Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19(2):414–419

    CAS  PubMed  Google Scholar 

  • Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104(12):3483–3489

    CAS  PubMed  Google Scholar 

  • Suzuki R, Kagami Y, Takeuchi K, Kami M, Okamoto M, Ichinohasama R, Mori N, Kojima M, Yoshino T, Yamabe H, Shiota M, Mori S, Ogura M, Hamajima N, Seto M, Suchi T, Morishima Y, Nakamura S (2000) Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96(9):2993–3000

    CAS  PubMed  Google Scholar 

  • Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2000) Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18(3):498–509

    CAS  PubMed  Google Scholar 

  • Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, Rohatiner AZ, Linch DC (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206–214. doi:10.1093/jnci/djk029 99/3/206 [pii]

    PubMed  Google Scholar 

  • Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, Wei W (2009) Duvic M (2012) Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to. Clin Cancer Res 18(18):5051–5060. doi:10.1158/1078-0432.CCR-12-0604 1078-0432.CCR-12-0604 [pii]

    Google Scholar 

  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994

    Google Scholar 

  • Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr (1991) Second cancers following non-Hodgkin’s lymphoma. Cancer 67(7):2002–2009

    CAS  PubMed  Google Scholar 

  • Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G (2011) Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 29(23):3194–3200. doi:10.1200/JCO.2011.35.0736 JCO.2011.35.0736 [pii]

    PubMed  Google Scholar 

  • Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Patterson BJ (2003) Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 21(22):4157–4164

    PubMed  Google Scholar 

  • Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107(1):108–115. doi:10.1002/cncr.21971

    PubMed  Google Scholar 

  • van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A (2010) Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28(17):2853–2858. doi:10.1200/JCO.2009.26.5827 JCO.2009.26.5827 [pii]

    PubMed Central  PubMed  Google Scholar 

  • Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC (1994) Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69(6):1088–1093

    CAS  PubMed Central  PubMed  Google Scholar 

  • von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 30(9):907–913. doi:10.1200/JCO.2011.38.5807 JCO.2011.38.5807 [pii]

    Google Scholar 

  • Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundstrom C, Christensson B, Sander B (2012) Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 156(2):225–233. doi:10.1111/j.1365-2141.2011.08942.x

    PubMed  Google Scholar 

  • Wahner-Roedler DL, Nelson DF, Croghan IT, Achenbach SJ, Crowson CS, Hartmann LC, O’Fallon WM (2003) Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo clinic experience. Mayo Clin Proc 78(6):708–715. doi:10.4065/78.6.708 S0025-6196(11)62460-9 [pii]

    PubMed  Google Scholar 

  • Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 98(10):2930–2934

    CAS  PubMed  Google Scholar 

  • Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT (2000) Management of breast cancer after Hodgkin’s disease. J Clin Oncol 18(4):765–772

    CAS  PubMed  Google Scholar 

  • Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH (2009) Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol 145(6):667–674 10.1001/archdermatol.2009.74145/6/667 [pii]

    PubMed  Google Scholar 

  • Wundisch T, Thiede C, Morgner A, Dempfle A, Gunther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdorffer E, Stolte M, Neubauer A (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 23(31):8018–8024. doi:10.1200/JCO.2005.02.3903 JCO.2005.02.3903 [pii]

    PubMed  Google Scholar 

  • Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, Osborne MP, Kinne DA, Rosen PP (1992) Breast cancer in patients irradiated for Hodgkin’s disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 10(11):1674–1681

    CAS  PubMed  Google Scholar 

  • Yang DH, Min JJ, Song HC, Jeong YY, Chung WK, Bae SY, Ahn JS, Kim YK, Bom HS, Chung IJ, Kim HJ, Lee JJ (2011) Prognostic significance of interim (1)(8)F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 47(9):1312–1318. doi:10.1016/j.ejca.2010.12.027 S0959-8049(11)00038-4 [pii]

    PubMed  Google Scholar 

  • Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20 + B-cell lymphoma in the rituximab era. J Clin Oncol 28(14):2373–2380. doi:10.1200/JCO.2009.26.2493

    CAS  PubMed  Google Scholar 

  • Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG (2006) Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 24(9):1376–1382. doi:10.1200/JCO.2005.03.6285 JCO.2005.03.6285 [pii]

    PubMed  Google Scholar 

  • Zinzani PL, Gandolfi L, Broccoli A, Argnani L, Fanti S, Pellegrini C, Stefoni V, Derenzini E, Quirini F, Baccarani M (2011) Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 117(5):1010–1018. doi:10.1002/cncr.25579

    PubMed  Google Scholar 

  • Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S (2012) Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39(1):4–12. doi:10.1007/s00259-011-1916-8

    PubMed  Google Scholar 

  • Zittoun R, Audebert A, Hoerni B, Bernadou A, Krulik M, Rojouan J, Eghbali H, Merle-Beral H, Parlier Y, Diebold J et al (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 3(2):207–214

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Cancer Institute, Duke University Medical Center, Morris Building, Room 05125A, 201 Trent Drive, Durham, NC, 27710, USA

    Chris R. Kelsey

  2. Department of Therapeutic Radiology, Yale University School of Medicine, LL 507, 35 Park Street, New Haven, CT, 06510, USA

    Lynn D. Wilson

Authors
  1. Chris R. Kelsey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynn D. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynn D. Wilson .

Editor information

Editors and Affiliations

  1. Department of Oncology, Nordland Hospital Trust Bodø University of Tromsø, Bodø, Norway

    Carsten Nieder

  2. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA

    Laurie E. Gaspar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kelsey, C.R., Wilson, L.D. (2013). Lymphoma. In: Nieder, C., Gaspar, L. (eds) Decision Tools for Radiation Oncology. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2013_830

Download citation

  • DOI: https://doi.org/10.1007/174_2013_830

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37101-1

  • Online ISBN: 978-3-642-37102-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation